Bias can be introduced into clinical trials if statistical methods are chosen based on subjective assessment of the trial data. Pre-specification of the planned analysis approach is essential to help reduce such bias. However, many trials fail to adequately pre-specify their statistical analysis approach, thereby allowing analysts to choose the method which gives the most favourable result. We propose a five-point framework for the pre-specification of the statistical analysis strategy for a clinical trial's primary outcome (the Pre-SPEC framework); this framework is designed to ensure that methods cannot be chosen based on the trial data in order to give a more favourable result. The five points are: (1) Prespecify before recruitment to the trial begins; (2) Specify a single primary analysis strategy; (3) Plan all aspects of the analysis; (4) Enough detail should be provided so that a third party could independently perform the analysis; and (5) Adaptive analysis strategies should use deterministic decision rules. This framework could be used as a template to help plan an analysis strategy, or to evaluate whether an existing strategy is at risk of bias due to inadequate pre-specification.
Introduction
Results from clinical trials depend upon the statistical methods used for analysis [1] [2] [3] [4] [5] . Different methods of analysis can lead to different conclusions around effectiveness and safety [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . When statistical methods are chosen or altered based on subjective assessment of the trial data, or multiple analyses are performed, then bias can be introduced through selective reporting of results [1-5, 7-10, 12, 15] . Pre-specification of the planned analysis approach is therefore important to prevent and identify subjective data-driven analyses and reporting [1-5, 7, 9, 10, 12] . The ICH-E9 (International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines require that the method of analysis for the trial's primary outcome be pre-specified in the trial protocol [1, 3, 4] .
However, many trials either fail to fully pre-specify their statistical analysis approach, or do so in a manner which allows subjective data-driven analyses or reporting (table 1) [2] [3] [4] [5] . For example, two reviews which examined trial protocols found that 11-20% of protocols did not specify the analysis model that would be used for the primary outcome, 42% did specify the model but omitted essential detail on how the model would be implemented, and 19% specified an approach that would allow the investigators to subjectively choose the final analysis model based on the trial data [2, 5] .
In this article, we propose a five point framework for pre-specification of the statistical analysis strategy for a trial's primary outcome (the Pre-SPEC framework). This framework is designed to ensure that methods cannot be chosen based on the trial data in order to give a more favourable result [2] [3] [4] , and is consistent with the principles outlined in the SPIRIT and ICH-E9 guidelines [1, 3, 4] .
The Pre-SPEC framework
We now outline the Pre-SPEC framework (box 1). The five points are: (1) Pre-specify before recruitment to the trial begins; (2) Specify a single primary analysis strategy; (3) Plan all aspects of the analysis; (4) Enough detail should be provided so that a third party could independently perform the analysis; and (5) Adaptive analysis strategies should use deterministic decision rules. We expand on each of these points below.
Pre-specify the analysis strategy before recruitment to the trial begins Pre-specifying the analysis strategy before the trial begins ensures the choice of methods is not influenced by any trial data. This can give readers confidence that trial results are not due to post-hoc model selection by the investigators [1, 3, 4] .
Specify a single primary analysis strategy
Specifying a single primary analysis strategy ensures investigators cannot perform multiple analyses and then selectively report the most favourable as their main approach. There are often valid reasons to specify additional methods of analysis, for instance to answer different questions about the intervention (e.g. the effect of a treatment policy vs the effect if everyone adheres [16] ), or to assess the robustness of the main results to different assumptions about the data (e.g. sensitivity analyses for missing data [17] ); in these instances, a single approach should be clearly labelled as the primary analysis strategy, with other approaches identified as sensitivity or supplementary analyses as appropriate [1, 3, 4] .
Plan all aspects of the statistical analysis
Omission of a particular aspect from the analysis strategy could allow investigators to run multiple analyses for that aspect, and selectively report the most favourable. For example, if the analysis population is not specified, investigators could run both an intention-to-treat and per-protocol analysis, and present whichever is most favourable.
Some of the essential aspects to cover are:
 Analysis population  Statistical model  The use of covariates  Handling of missing data For many trials there will be additional aspects to cover; for instance, a trial using a Bayesian analysis would need to pre-specify what prior would be used for the primary analysis; a non-inferiority trial would need to specify the non-inferiority margin; and a trial where post-randomisation events such as use of rescue medication are likely to occur would need to specify how these events would be handled in the analysis, if relevant.
It is also useful to specify the type of treatment effect that is to be estimated (the estimand) [16] and what information will be presented from the analysis, such as the level of the confidence interval and the threshold for statistical significance if applicable.
Enough detail should be provided so that a third party could independently perform the analysis There is often a substantial amount of detail required to implement an analysis. For example, using multiple imputation for missing data requires specification of the method of imputing data; this includes specifying which variables are included in the imputation model (and how they are included), whether multivariate normal, chained equations or some other imputation approach is used, the number of imputed datasets, and how imputed datasets will be combined. Simply stating that multiple imputation will be used is not sufficient, as this allows the investigator to carry out multiple analyses based on different imputation approaches.
Fully pre-specifying these details to such a degree that a third party could independently perform the analysis helps to ensure investigators cannot perform multiple analyses. A good test of whether there is sufficient detail is to write out the statistical code that would be used to implement the analysis in a statistical software program; if investigators are unable to write out their planned code, this likely means the analysis strategy is not sufficiently well specified.
In addition, providing this code in the protocol as a supplement to a description of the planned analysis can be extremely helpful, as this leaves no room for ambiguity, and ensures all necessary detail is provided.
Adaptive analysis strategies should use deterministic decision rules
Sometimes investigators use adaptive analysis strategies, where some aspect of the final analysis is chosen based on the trial data. For instance, they may specify that either multiple imputation or a complete case analysis will be used depending on the level of missing data. However, adaptive analysis strategies can be problematic if the decision rules are subjective, as this allows investigators to perform each potential analysis and selectively report the most favourable. For example, without a clear rule about when to use multiple imputation vs. complete cases, analysts could perform both and then select whichever gives a preferable result.
In order to prevent decisions from being driven by results, adaptive analysis strategies should use deterministic decision rules for selection of the final analysis approach. This removes the investigators ability to influence decisions, and therefore will not introduce bias through selective reporting. In the example above, investigators could specify that multiple imputation will be used if the level of missing data is >10%, and a complete case analysis will be used otherwise.
Sometimes investigators try to reduce the possibility of bias from subjective decision rules through other means, for instance by using a blinded dataset with treatment allocation codes removed to select the final analysis approach. We do not favour such approaches, as they generally do not ensure that bias cannot be introduced through the subjective application of the decision rules. For example, an investigator using a blinded dataset to select baseline covariates to include in the analysis model could systematically choose covariates which substantially lowered the residual standard deviation of the outcome; this could lead to an underestimate of the standard error, leading to confidence intervals that are too narrow and p-values that are too small [18] . Another drawback is that it is difficult to verify that these decisions were indeed based on the blinded data, rather than the unblinded dataset. As such, we do not consider trials which use subjective decision rules as being fully pre-specified.
Finally, we note that in some instances adaptive analysis strategies can lead to biased estimates or incorrect standard errors even when decision rules are fully deterministic; this typically occurs when the decision rule is correlated with the size of the treatment effect or its standard error. Some examples of this are available in the following references [18] [19] [20] . Therefore, caution should be applied when considering adaptive strategies, even if deterministic decision rules are planned.
Example
We now illustrate our framework in an example. Consider the following analysis section from a trial protocol for a continuous outcome measured at multiple follow-up time-points:
" 
Evaluating whether the analysis approach is fully pre-specified
This analysis approach meets our first two points; it was described in the trial protocol before recruitment began, and consists of a single overall analysis strategy.
For our third point, the analysis approach covers three analysis aspects (population, analysis model, covariates), however it does not specify how missing data will be handled. We can guess that patients with missing outcome data at certain follow-up time-points will be excluded from the analysis at those time-points, however this is not entirely clear.
For our fourth point, there is insufficient detail for a third party to independently replicate the analysis model; there are numerous ways to implement a mixed-model repeated measures analysis (for instance, different approaches to specifying random-effects, or different correlation structures to model the correlation between outcomes from the same patient), and it is not clear which approach the authors intend to use.
For our fifth point, the authors plan to use adaptive analysis strategies for two components; which covariates to include in the analysis, and whether to transform the outcome (and if so, which transformation to use). In both instances, there are no deterministic decision rules on how the final analysis approach should be decided (e.g. for covariates, there is no definition of what quasi-significant means), which would allow the analyst to subjectively choose the approach based on the final trial data.
Therefore, the specified analysis approach could allow the analyst to implement a number of different analysis strategies (relating to handling of missing data, the analysis model, covariates, and transformation of the outcome) and present the most favourable results. As such, this approach cannot be considered fully pre-specified.
Modifying the analysis approach so it is fully pre-specified We can make this approach fully pre-specified by resolving the issues relating to points 3-5 above. First, we could explicitly state that patients with missing outcome data at certain follow-up time-points will be excluded from the analysis at these time-points. Second, we could provide additional information on how the analysis model will be implemented; for instance, we could specify a linear mixed-effects model with an unstructured correlation matrix for observations at different time-points, estimated using restricted maximum likelihood. We could supplement this description by including the planned statistical code to remove any ambiguity from our description (see below for example Stata code).
Finally, we need to resolve the issues around the adaptive analysis strategies related to the stratification variables and the transformation of the outcome. In this scenario, it is unlikely that the adaptive strategies are necessary, or even beneficial. All stratification variables should be included in the model regardless of statistical significance, as failure to do so can lead to incorrect confidence intervals and pvalues [21, 22] . Furthermore, linear regression models are usually very robust to violations of distributional assumptions [23] , and transformation can lead to issues of interpretability (in particular, categorisation could lead to a substantial reduction in power [24] ). Therefore, the simplest way to resolve this issue is to remove the adaptive part, and use a strategy which includes all stratification variables in the model and does not consider transformations of the outcome. If the adaptive strategy was deemed necessary, then a deterministic decision rule would need to be specified, for example by giving the exact p-value threshold for retaining stratification variables in the model (though we note this approach can be problematic even if fully pre-specified [18] ).
Incorporating these changes, we could re-write the planned analysis strategy as follows: We note that Stata automatically excludes time points with missing outcomes from the analysis, and so does not require additional code to perform this step. Further, we note that the above strategy is not necessarily the optimal statistical approach, but is used simply to illustrate how the original approach could be fully pre-specified.
Discussion
In clinical trials, it is important to assess whether investigators have pre-specified their statistical methods in advance, and whether they have followed what they said. Inadequate pre-specification or deviations from the pre-specified approach can allow investigators to perform multiple analyses and selectively report the most favourable. The Pre-SPEC framework provides guidance on how to ensure statistical methods are fully pre-specified to an extent that does not allow investigators subjective flexibility in which analyses to perform or report. This framework is consistent with the principles outlined in the SPIRIT and ICH-E9 guidelines; a comparison is provided in the supplementary material.
We do note that there are sometimes good reasons for investigators to change their statistical methods during the course of the trial, for instance because of an advance in statistical methodology or implementation of new methods in statistical software packages. Changes are acceptable, provided they are explained and justified [15] ; however, a complete description of what was planned is necessary for readers to evaluate to what extent changes may have affected results, and whether the changes were justified.
It is sometimes argued that statistical methods, even for a trial's primary outcome, can go in a standalone statistical analysis plan, rather than in the protocol. However, statistical analysis plans are infrequently made publicly available and are often written after the trial has started. We therefore agree with the recommendations of the SPIRIT and ICH-E9 guidelines which state that the statistical methods for a trial's primary outcome should be fully pre-specified in the trial protocol.
In conclusion, the Pre-SPEC framework can be used to ensure that statistical analyses are fully prespecified. It is consistent with the principles outlined in SPIRIT and ICH-E9 and should increase statistical rigour and transparency in clinical trials. a Based on references [5] and [2] b 15/99 protocols gave insufficient detail around how they planned to implement multiple imputation, 2/99 protocols but gave insufficient detail around their planned inverse probability weighting procedure Box 1 -Framework for pre-specifying a statistical analysis strategy (Pre-SPEC) Pre-specify before recruitment Pre-specify the analysis strategy before recruitment to the trial begins.
Single analysis strategy Specify a single primary analysis strategy.
Plan all aspects All aspects of the planned analysis should be covered, including analysis population, statistical model, covariates, and handling of missing data.
Enough detail
Provide sufficient detail to allow a third party to independently perform the analysis (ideally through statistical code).
Choices made deterministically
For adaptive analysis strategies which use the trial data to inform some aspect of the analysis, use deterministic decisionrules that prevent analysis choices being driven by results.
